EDAP Installs Ablatherm Robotic® HIFU at Leading Academic Medical Center
September 12 2016 - 8:30AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, today announced the signature of a contract for the
installation of Ablatherm Robotic HIFU at the renowned Duke
University Hospital located in Durham, North Carolina.
Marc Oczachowski, EDAP TMS Chief Executive Officer,
said: “The signature of this contract with the prestigious Duke
University Hospital is a big accomplishment and great news for
EDAP. Dr Cary Robertson and Duke University Hospital were involved
with EDAP as a primary investigator site for our PMA. We are
extremely pleased and proud to count them among our Ablatherm
Robotic HIFU users and use our state of the art HIFU technology on
a routine basis. Also this is another milestone in the growing
adoption of our HIFU device among leading physicians in the urology
space.”
Duke University Hospital in Durham, North Carolina,
is consistently recognized by leading publications such U.S. News
& World Report and TIME as one of the world’s leading
healthcare institutions.
About EDAP TMS SAEDAP TMS SA
markets today Ablatherm® for high-intensity focused ultrasound
(HIFU) for prostate tissue ablation in the U.S. and for treatment
of localized prostate cancer in the rest of the world. HIFU
treatment is shown to be a minimally invasive and effective option
for prostatic tissue ablation with a low occurrence of side
effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for
surgery or who prefer an alternative option, or for patients who
failed radiotherapy treatment. Ablatherm-HIFU is approved for
commercial distribution in Europe and some other countries
including Mexico and Canada, and has received 510(k) clearance by
the U.S. FDA. The Company also markets an innovative robot-assisted
HIFU device, the Focal One®, dedicated to focal therapy of prostate
cancer. Focal One® is CE marked but is not FDA approved. The
Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and distributes medical equipment (the Sonolith®
lithotripters’ range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
Forward-Looking StatementsIn
addition to historical information, this press release may contain
forward-looking statements. Such statements are based on
management’s current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company’s filings
with the Securities and Exchange Commission and in particular, in
the sections “Cautionary Statement on Forward-Looking Information”
and “Risk Factors” in the Company’s Annual Report on Form 20-F.
Contact:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Lee Roth
The Ruth Group
646-536-7012
lroth@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024